Special Considerations in Atopic Dermatitis in Young Children
- PMID: 39278714
- DOI: 10.1016/j.det.2024.05.003
Special Considerations in Atopic Dermatitis in Young Children
Abstract
Atopic dermatitis (AD) begins in early childhood in the majority of children. Addressing AD in small children includes recognition of the early presentations of disease in all skin types, triggers, comorbidities, and therapeutics. These include risk of medication absorption, more xerosis, infections, and creating management plans that are acceptable to parents/caregivers, while offering safety. Vaccination efficacy, safety on systemic agents, growth and development, tactile sensory development, and teething-related facial eruptions of early childhood are additional concerns. Prevention of long-term comorbidities is the highest goal. Using age-based considerations helps support excellence in care and improved patient-parent experience.
Keywords: Atopic dermatitis; Comorbidities; Dupilumab; Teething; Vaccination.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure Dr Mudra Chatt has no conflicts to declare. Dr Karan Lal has the following conflicts; Incyte (speaker), Abbvie (speaker), Pfizer (speaker), Boehringer Ingelheim (speaker), Galderma (speaker), Aerolase (speaker), Sanofi (speaker). Dr Nanette Silverberg is an investigator of Avita, and advisor/ consultant/ speaker for Avita, Incyte, Novan, Pfizer, Regeneron, Sanofi, and Verrica.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources